CBTF Programs and Research

Larotrectinib led to rapid/durable responses and high disease control rates in children with TRK fusion-position central nervous system cancers.

Jacki Garcia, RN, BSN, CNRN; and Kristin Hendrickson, BA, RN, discuss phase 0 trials and how they can help expedite the research process for brain cancer therapies.

The FDA granted elraglusib a rare pediatric disease designation for Ewing sarcoma based on findings from the 1/2 Actuate-1902 trial.

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

The FDA approved a companion diagnostic for vorasidenib for patients with grade 2 astrocytoma or oligodendroglioma.

An investigational formula of panobinostat called MTX110 may improve outcomes in patients with recurrent glioblastoma.